Table 1.
Demographic characteristics of the elderly COVID-19 patients, treatments, and outcomes
| Case No. | Age, years | Sex | Skin color | Comorbidities | Treatments | Outcomes |
|---|---|---|---|---|---|---|
| 12 | 95 | F | White | Hypertension, ischemic heart disease, malnutrition, dementia | Itolizumab (2 doses), IFN-α2B, Kaletra, chloroquine, LMWH, parenteral vitamins | Alive |
| 13 | 83 | M | White | Hypertension, chronic obstructive pulmonary disease, dementia | Itolizumab (2 doses), IFN-α2B, Kaletra, chloroquine, LMWH, parenteral vitamins | Alive |
| 14 | 78 | F | White | Malnutrition, dementia | Itolizumab (2 doses), IFN-α2B, Kaletra, chloroquine, LMWH, parenteral vitamins | Alive |
| 15 | 85 | F | Black | Hypertension, diabetes mellitus, malnutrition, dementia | Itolizumab (2 doses), Kaletra, chloroquine, LMWH, parenteral vitamins, antibiotics | Alive |
| 16 | 75 | F | White | Hypertension, diabetes mellitus, chronic obstructive pulmonary disease, asthma, malnutrition | Itolizumab (2 doses), IFN-α2B, Kaletra, chloroquine, LMWH, parenteral vitamins | Alive |
| 17 | 68 | M | White | Hypertension, diabetes mellitus, chronic obstructive pulmonary disease, dementia, smoking, hypertensive heart disease | Itolizumab (2 doses), IFN-α2B, Kaletra, chloroquine, LMWH, parenteral vitamins | Alive |
| 18 | 78 | F | NA | Dementia, anemia | Itolizumab (2 doses), IFN-α2B, Kaletra, chloroquine, LMWH, antibiotics | Alive |
| 19 | 88 | F | White | Hypertension, diabetes mellitus, ischemic heart disease, malnutrition | Itolizumab (2 doses), Kaletra, chloroquine, LMWH, antibiotics | Alive |
| 20 | 89 | F | White | Hypertension, ischemic heart disease, heart disease | Itolizumab (2 doses), IFN-α2B, Kaletra, chloroquine, heparin, antibiotics | Alive |
| 21 | 64 | M | White | Hypertension, chronic obstructive pulmonary disease | Itolizumab (2 doses), IFN-α2B, Kaletra, chloroquine, heparin, vitamins | Alive |
| 22 | 80 | F | White | Hypertension, diabetes mellitus, ischemic heart disease, dementia | Itolizumab (2 doses), Kaletra, chloroquine, LMWH, parenteral vitamins | Alive |
| 24 | 79 | F | White | Hypertension, ischemic heart disease, malnutrition, dementia | Itolizumab (2 doses), Kaletra, chloroquine, LMWH, parenteral vitamins | Alive |
| 25 | 64 | M | White | Hypertension, diabetes mellitus, malnutrition, dementia, lower limbs amputated | Itolizumab (2 doses), IFN-α2B, Kaletra, chloroquine, LMWH, parenteral vitamins | Alive |
| 26 | 70 | F | Black | Hypertension, ischemic heart disease, malnutrition, dementia | Itolizumab (2 doses), IFN-α2B, Kaletra, chloroquine, LMWH, parenteral vitamins | Dead |
| 27 | 100 | F | Black | Hypertension, ischemic heart disease, malnutrition, dementia | Itolizumab (2 doses), Kaletra, chloroquine, LMWH, parenteral vitamins | Alive |
| 32 | 81 | F | NA | Hypertension, ischemic heart disease, chronic obstructive pulmonary disease, malnutrition | Itolizumab (2 doses), IFN-α2B, Kaletra | Alive |
| 40 | 86 | M | White | None | Itolizumab (1 dose), IFN-α2B, Kaletra, chloroquine, heparin, erythropoietin | Alive |
| 43 | 67 | M | Brown | Obesity, smoking, alcoholism, posttraumatic paraplegia | Itolizumab (2 doses), Kaletra, chloroquine, heparin, erythropoietin | Alive |
| 44 | 71 | M | White | None | Itolizumab (1 dose), IFN-α2B, Kaletra, chloroquine, antibiotics, erythropoietin, steroids, omeprazole | Alive |
IFN-α2B, interferon alpha 2B; LMWH, low-molecular-weight heparin; NA, not available.